High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Purpose
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation treatment and can cause severe pain, dysphagia, and weight loss resulting in feeding tube placement, worse health-related quality of life, treatment interruptions, unplanned hospitalizations, and significant financial burden. Mucositis pain is often treated with opioid pain medications which do provide pain relief but have many known side effects not limited to mental clouding, constipation, fatigue, endocrinopathy, neurotoxicity, sleep-disordered breathing, and most distressingly persistent opioid use. Gabapentin may help relieve pain from oral mucositis caused by radiation while also reducing the need for opiate pain medications for patients receiving chemotherapy and radiation for squamous cell carcinoma of the head and neck region
Conditions
- Head and Neck Squamous Cell Carcinoma
- Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Histologic documentation of disease: Squamous cell carcinoma of the head and neck region. * Stage: I-IV - No prior treatment for head and neck cancer - Planned treatment with cisplatin-based chemoradiation therapy (weekly or once every 3 weeks [q 3 week]) - Able to swallow capsules whole - No known hypersensitivity to gabapentin or its ingredients - No patients on dialysis or with transplanted organs - No prior surgery or radiation for head and neck cancer and/or are being treated for recurrent head and neck cancer. Patients with a history of surgery and radioactive iodine for the treatment of thyroid cancer are eligible. Concurrent cancer therapy for other cancers is not allowed - No planned surgery or chemotherapy or immunotherapy following 7 weeks of standard chemoradiation treatment - No known brain metastases - No nonprescribed use of any opioids (including heroin) within 6 months prior to registration - No prescribed medications for chronic and/or long-term pain and/or neuropathy, including patients under treatment of a pain specialist or substance abuse programs. Acute post-biopsy medications are allowed if the patient has discontinued them 3 days prior to study registration - No current treatment with mefloquine - Age ≥ 18 years - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 - Creatinine ≤ 1.5 x upper limit of normal (ULN) - Not pregnant and not nursing, because this study involves both radiation and chemotherapy. In addition, the genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential, a negative pregnancy test done < 7 days prior to registration is required. Women must agree to using contraception for the duration of receiving study drugs and for 6 months after completing chemoradiation - Not taking medications for a psychotic psychiatric illness - No existing diagnosis of sleep apnea - No acute narrow-angle glaucoma - No uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - No investigational agent within 30 days prior to registration - No enrollment on other studies of systemic pain control agents - Language: In order to complete the mandatory patient-completed measures, participants must be able to speak and read English or Spanish - Patients with impaired decision making are not eligible for study
Exclusion Criteria
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Supportive Care
- Masking
- Triple (Participant, Care Provider, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Placebo Comparator Arm I (Placebo) |
Starting by radiation treatment 8, patients receive placebo PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study. |
|
|
Experimental Arm II (Gabapentin) |
Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study. |
|
Recruiting Locations
Gilbert, Arizona 85297
Peoria, Arizona 85381
Site Public Contact
623-773-2873
Phoenix, Arizona 85016
Phoenix, Arizona 85027
Scottsdale, Arizona 85251
Scottsdale, Arizona 85258
Surprise, Arizona 85374
Tempe, Arizona 85284
Bakersfield, California 93301
Site Public Contact
661-323-4673
Dublin, California 94568
Site Public Contact
877-642-4691
Fremont, California 94538
Fresno, California 93720
Site Public Contact
833-574-2273
Modesto, California 95356
Site Public Contact
877-642-4691
Modesto, California 95356
Oakland, California 94611
Roseville, California 95661
Sacramento, California 95814
Sacramento, California 95823
San Francisco, California 94115
San Jose, California 95119
San Leandro, California 94577
San Rafael, California 94903
Santa Clara, California 95051
Santa Rosa, California 95403
South San Francisco, California 94080
Vallejo, California 94589
Walnut Creek, California 94596
Lakewood, Colorado 80228
Honolulu, Hawaii 96819
Boise, Idaho 83712
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Aurora, Illinois 60504
Aurora, Illinois 60506
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carthage, Illinois 62321
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Eureka, Illinois 61530
Galesburg, Illinois 61401
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Moline, Illinois 61265
Site Public Contact
309-779-2000
Normal, Illinois 61761
Normal, Illinois 61761
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Oak Lawn, Illinois 60453
Ottawa, Illinois 61350
Palos Heights, Illinois 60463
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Peoria, Illinois 61615
Peru, Illinois 61354
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Washington, Illinois 61571
Ames, Iowa 50010
Site Public Contact
515-956-4132
Ames, Iowa 50010
Cedar Rapids, Iowa 52402
Cedar Rapids, Iowa 52403
Site Public Contact
319-365-4673
Cedar Rapids, Iowa 52403
Site Public Contact
319-363-2690
Fort Dodge, Iowa 50501
Site Public Contact
515-956-4132
Marshalltown, Iowa 50158
Site Public Contact
515-956-4132
Bemidji, Minnesota 56601
Saint Cloud, Minnesota 56303
Cape Girardeau, Missouri 63703
Joplin, Missouri 64804
St Louis, Missouri 63128
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Anaconda, Montana 59711
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59804
Bellevue, Nebraska 68123
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68118
Site Public Contact
402-559-5600
Omaha, Nebraska 68198
Buffalo, New York 14263
Forest Hills, New York 11375
Site Public Contact
718-520-6620
Lake Success, New York 11042
Site Public Contact
516-734-8896
New York, New York 10065
Site Public Contact
212-434-4460
New York, New York 10075
Site Public Contact
516-734-8896
Rego Park, New York 11374
Site Public Contact
718-312-3446
The Bronx, New York 10461
The Bronx, New York 10467
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Canton, Ohio 44710
Oklahoma City, Oklahoma 73104
Danville, Pennsylvania 17822
Dickson City, Pennsylvania 18519
Erie, Pennsylvania 16505
Erie, Pennsylvania 16544
Site Public Contact
814-452-5000
Farrell, Pennsylvania 16121
Greensburg, Pennsylvania 15601
Site Public Contact
724-838-1900
Harrisburg, Pennsylvania 17109
Jefferson Hills, Pennsylvania 15025
Lewisburg, Pennsylvania 17837
Mechanicsburg, Pennsylvania 17050
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
Monroeville, Pennsylvania 15146
Monroeville, Pennsylvania 15146
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19114
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-621-2334
Pittsburgh, Pennsylvania 15243
Site Public Contact
412-502-3920
Pottsville, Pennsylvania 17901
Seneca, Pennsylvania 16346
Site Public Contact
814-676-7900
Wexford, Pennsylvania 15090
Wilkes-Barre, Pennsylvania 18711
Willow Grove, Pennsylvania 19090
Greer, South Carolina 29651
Spartanburg, South Carolina 29303
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57117-5134
Farmington, Utah 84025
Salt Lake City, Utah 84106
Salt Lake City, Utah 84112
South Jordan, Utah 84009
Bridgeport, West Virginia 26330
Martinsburg, West Virginia 25401
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Princeton, West Virginia 24740
Site Public Contact
304-487-7515
Wheeling, West Virginia 26003
Site Public Contact
304-243-6442
Antigo, Wisconsin 54409
Burlington, Wisconsin 53105
Cudahy, Wisconsin 53110
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
La Crosse, Wisconsin 54601
Marinette, Wisconsin 54143
Medford, Wisconsin 54451
Menomonee Falls, Wisconsin 53051
Site Public Contact
262-257-5100
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Oak Creek, Wisconsin 53154
Site Public Contact
414-805-0505
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rhinelander, Wisconsin 54501
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54481
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Site Public Contact
877-405-6866
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
West Bend, Wisconsin 53095
Site Public Contact
414-805-0505
Wisconsin Rapids, Wisconsin 54494
Site Public Contact
715-422-7718
More Details
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To determine whether prophylactic high dose gabapentin, titrated to a dose of 3600 mg (1200 mg three times per day [TID]), is superior to placebo in increasing the proportion of patients not needing opiates while undergoing chemoradiation therapy. SECONDARY OBJECTIVES: I. To determine whether prophylactic high dose gabapentin is superior to placebo in prolonging the time to first opioid use while undergoing chemoradiation therapy. II. To determine whether prophylactic high dose gabapentin is superior to placebo in improving patient reported pain scores using the 0-10 numerical rating scale (NRS) from baseline to 4 weeks after the end of chemoradiation therapy. EXPLORATORY OBJECTIVES: I. To explore the duration of opioid use from the time of initiation to cessation by arm as well as describe the proportion of patients remaining on opioids at 3 months, 6 months, and 1 year by arm. II. To explore the trajectory of patient reported symptom and quality of life outcomes using the Oral Mucositis Weekly Questionnaire (OMWQ) by arm. III. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-30 (EORTC QLQ-30) by arm. IV. To explore the trajectory of patient reported symptom and quality of life outcomes using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck-43 (EORTC QLQ-H&N43) by arm. V. To evaluate the adverse event profiles of prophylactic high dose gabapentin versus placebo. VI. To assess the tolerance of high dose gabapentin. VII. To explore the trajectory of patient health using patient body mass index (BMI) and creatinine, absolute neutrophil count (ANC) as routinely obtained by arm. VIII. To describe the incidence of feeding tube requirement during and after chemoradiation therapy by arm. IX. To describe the dose of prescribed opioids standardized using the Morphine Milligram Equivalent calculator by arm. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Starting by radiation treatment 8, patients receive placebo orally (PO) once daily (QD) on day 1, twice daily (BID) on day 2, then three times daily (TID) starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with placebo continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive placebo TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study. ARM II: Starting by radiation treatment 8, patients receive gabapentin PO QD on day 1, BID on day 2, then TID starting day 3 onward. Patients also receive standard of care radiation, chemotherapy and pain medications. Treatment with gabapentin continues in the absence of disease progression or unacceptable toxicity, until the symptoms of oral mucositis and other treatment effects begin to resolve and other pain medications has been stopped. Patients then continue to receive gabapentin TID for 9 additional days, at sequentially smaller doses, then BID for 1 day and QD for one day before stopping. Patients undergo blood sample collection throughout the study. After completion of study treatment, patients are followed up at 4 weeks, 3 months and 6 months after the last dose of chemoradiation therapy.